AstraZeneca Q2 Adj. EPS $0.99 Misses $1.20 Estimate, Sales $12.98B Beat $12.75B Estimate
$AZN
Biotechnology: Pharmaceutical Preparations
Health Care
AstraZeneca (NASDAQ:AZN) reported quarterly adjsuted earnings of $0.99 per share which missed the analyst consensus estimate of $1.20 by 17.5 percent. This is a 7.91 percent decrease over earnings of $1.07 per share from the same period last year. The company reported quarterly sales of $12.98 billion which beat the analyst consensus estimate of $12.75 billion by 1.83 percent. This is a 13.73 percent increase over sales of $11.42 billion the same period last year.